Table 1. Characteristics of 98 breast cancer patients treated with anti-Her-2 therapy.
| Characteristic | n (%) |
|---|---|
| Age at diagnosis, years | |
| Median age | 47 (Range 26~76) |
| >50 | 41(42%) |
| ≤50 | 57(58%) |
| Menopausal status | |
| Pre | 56(57%) |
| Post | 42(43%) |
| Tumor size | |
| >2cm | 51(52%) |
| ≤2cm | 32(33%) |
| Unavailable | 15(15%) |
| Nodal status | |
| N0 | 25(26%) |
| N1 | 29(30%) |
| N2 | 22(22%) |
| N3 | 12(12%) |
| Unavailable | 10(10%) |
| Estrogen receptor status | |
| Positive | 35(36%) |
| Negative | 63(64%) |
| Progestrone receptor status | |
| Positive | 53(54%) |
| Negative | 45(16%) |
| HER2/neu status(IHC) | |
| Positive | 84(86%) |
| NegativeA | 12(12%) |
| UnavailableB | 2(2%) |
| TNM stage at diagnosis | |
| I | 9(9%) |
| II | 35(36%) |
| III | 34(35%) |
| IV | 17(17%) |
| Unavailable | 3(3%) |
| Intratumoral TILs | |
| <10% | 82(84%) |
| ≥10% | 16(16%) |
| Stromal TILs | |
| <10% | 41(42%) |
| ≥10% | 57(58%) |
| Chemotherapy regimenC | |
| A/T | 46(47%) |
| A+T | 45(46%) |
| others | 7(7%) |
Abbreviation: TILs, tumor-infiltrating lymphocytes; A/T, anthracycline or taxol based regimen; A+T, anthracycline and taxol based regimen; A: FISH test result was unavailable; B: both IHC and FISH results were unavailable; C: all regimens included anti-Her-2 therapy (trastuzumab);